This pioneering research article explains the benefits of cannabinoid-based medicines for heart disease therapies based on scientific research.
LAS VEGAS, Aug. 2, 2018 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the publication of a review article co-authored by GB Sciences and key collaborators in the Journal of the American Heart Association, which explains the potential medical benefits of using cannabinoid-based therapies for the treatment of heart diseases. GB Sciences' own Chief Science Officer, Dr. Andrea Small-Howard, joins co-authors including Dr. Alexander Stokes, President of Makai Biotechnology, LLC, and Dr. Helen Turner, VP of Innovation and Dean of the Division of Natural Sciences and Mathematics at Chaminade University, in expounding on this very important subject in "Cannabinoids, the Heart of the Matter". The link to the article is found at http://dx.doi.org/10.1161/JAHA.118.009099. While there have been recent studies supporting the use of cannabinoids for seizure disorders, most people and many scientists are not aware of the potential uses for cannabinoids in treating cardiac hypertrophy and other heart diseases.
"With the recent FDA approval of GW Pharma's cannabinoid-based drug, Epidiolex, people are becoming more aware that cannabinoid-based therapies can have significant medical benefits for patients with seizures caused by Lennox-Gastaut or Dravet Syndrome," explains Dr. Small-Howard, "but we wanted to bring attention to the potential life-saving applications of cannabinoids for the treatment of heart conditions through the manipulation of specific-cannabinoid sensitive receptors."
In December of 2016, GB Sciences licensed patents on methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1, from Dr. Stokes of Makai Biotechnology. GB remains committed to cannabis-based therapies for heart disease, as demonstrated by their filing original patent applications on the use of myrcene-based complex mixtures for heart disease in May of 2017 and another patent application on cannabinoid and terpenoid-based complex mixtures for the treatment of heart disease through manipulation of cannabis-receptors in May of 2018.
John Poss, CEO of GB Sciences says, "Heart disease is still the leading global cause of death, and cannabinoid-based therapeutics are a promising new option for its treatment. At GB Sciences, we are committed to broadening the scope of scientific research using novel applications of cannabinoid therapies and rigorously demonstrating their effectiveness."
About Makai Biotechnology, LLC
Makai Biotechnology, LLC is a Hawaii-based cardiovascular therapy company established by Dr. Alexander J. Stokes, Assistant Professor at the University of Hawaii, John A Burns School of Medicine. Makai Biotechnology is developing novel therapies for the treatment of heart failure. A novel ion channel target has been identified that modulates heart disease. Under the direction of Dr. Alexander Stokes, Makai Biotechnology has validated multiple effective compounds that regulate this target. Makai Biotechnology plans to establish alliances with major pharmaceutical companies to develop and test compounds from pre-clinical through phase II human clinical trials.
About Chaminade University
Located in the international city of Honolulu on the island of O`ahu, Chaminade is regarded for its remarkably diverse student body–students come from the Hawai`i, the mainland U.S., the Pacific region, and beyond. Class sizes are small, with a low student-to-faculty ratio. Here, students develop professionally through service learning projects, research and internship experiences, and leadership and community networking opportunities. At Chaminade, students receive a personalized education that prepares them for an ever-changing future.
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.